ALK and atherosclerosis: To determine whether mAb2 could be exploited as a translational tool impacting atherosclerosis, three cohorts of Ldlr−/− mice were fed a WD for either 6 weeks (initiation study) or 12 weeks (progression study) and administered phosphate-buffered saline (PBS), rat IgG1 or anti-ALK1 mAb2.